- Home
- ANVS vs SRTS Comparison
ANVS vs SRTS Comparison
Compare ANVS & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- SRTS
- Stock Information
- Founded
- ANVS 2008
- SRTS 2010
- Country
- ANVS United States
- SRTS United States
- Employees
- ANVS N/A
- SRTS N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- ANVS Health Care
- SRTS Health Care
- Exchange
- ANVS Nasdaq
- SRTS Nasdaq
- Market Cap
- ANVS 53.3M
- SRTS 52.9M
- IPO Year
- ANVS 2020
- SRTS 2016
- Fundamental
- Price
- ANVS $3.69
- SRTS $4.04
- Analyst Decision
- ANVS Strong Buy
- SRTS Strong Buy
- Analyst Count
- ANVS 3
- SRTS 3
- Target Price
- ANVS $13.50
- SRTS $8.00
- AVG Volume (30 Days)
- ANVS 3.0M
- SRTS 164.5K
- Earning Date
- ANVS 11-12-2025
- SRTS 11-06-2025
- Dividend Yield
- ANVS N/A
- SRTS N/A
- EPS Growth
- ANVS N/A
- SRTS N/A
- EPS
- ANVS N/A
- SRTS N/A
- Revenue
- ANVS N/A
- SRTS $35,609,000.00
- Revenue This Year
- ANVS N/A
- SRTS N/A
- Revenue Next Year
- ANVS N/A
- SRTS $47.33
- P/E Ratio
- ANVS N/A
- SRTS N/A
- Revenue Growth
- ANVS N/A
- SRTS N/A
- 52 Week Low
- ANVS $1.11
- SRTS $3.03
- 52 Week High
- ANVS $7.52
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- ANVS 77.19
- SRTS 55.77
- Support Level
- ANVS $2.11
- SRTS $3.76
- Resistance Level
- ANVS $4.00
- SRTS $4.69
- Average True Range (ATR)
- ANVS 0.35
- SRTS 0.40
- MACD
- ANVS 0.15
- SRTS 0.03
- Stochastic Oscillator
- ANVS 70.34
- SRTS 57.48
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.